US20100016593A1 - Crystalline forms of palonosetron hydrochloride - Google Patents
Crystalline forms of palonosetron hydrochloride Download PDFInfo
- Publication number
- US20100016593A1 US20100016593A1 US12/311,819 US31181907A US2010016593A1 US 20100016593 A1 US20100016593 A1 US 20100016593A1 US 31181907 A US31181907 A US 31181907A US 2010016593 A1 US2010016593 A1 US 2010016593A1
- Authority
- US
- United States
- Prior art keywords
- hcl
- mixture
- water
- pal
- palonosetron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 title claims abstract description 79
- 229960003359 palonosetron hydrochloride Drugs 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 91
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 46
- 239000000725 suspension Substances 0.000 claims description 43
- 239000002904 solvent Substances 0.000 claims description 27
- 238000001144 powder X-ray diffraction data Methods 0.000 claims description 24
- 238000010992 reflux Methods 0.000 claims description 21
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 23
- 239000000243 solution Substances 0.000 description 42
- 239000007787 solid Substances 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- -1 preferably Substances 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 229940032147 starch Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960002131 palonosetron Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- IGNPOXGBNFMJHE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-2-amine Chemical compound C1CN2C(N)CC1CC2 IGNPOXGBNFMJHE-UHFFFAOYSA-N 0.000 description 2
- DIDFYSQVOPVZQB-QGZVFWFLSA-N 2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5,6-dihydro-4h-benzo[de]isoquinolin-1-one Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2C3=C1 DIDFYSQVOPVZQB-QGZVFWFLSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007942 layered tablet Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- VDLWTJCSPSUGOA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCCC2=C1 VDLWTJCSPSUGOA-UHFFFAOYSA-N 0.000 description 1
- JKERXBZCPHYIGM-UHFFFAOYSA-N 2,3,3a,4,5,6-hexahydrobenzo[de]isoquinolin-1-one;hydrochloride Chemical compound Cl.C1CCC2=CC=CC3=C2C1CNC3=O JKERXBZCPHYIGM-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- HCMHNQIZZVMXJJ-UNTBIKODSA-N B.[H][C@@]1(NC(=O)C2=C3CCCCC3=CC=C2)CN2CCC1CC2 Chemical compound B.[H][C@@]1(NC(=O)C2=C3CCCCC3=CC=C2)CN2CCC1CC2 HCMHNQIZZVMXJJ-UNTBIKODSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- RNTGAALAVHDESG-UNTBIKODSA-N C.[H][C@@]1(N2/C=C3/CCCC4=CC=CC(=C43)C2=O)CN2CCC1CC2 Chemical compound C.[H][C@@]1(N2/C=C3/CCCC4=CC=CC(=C43)C2=O)CN2CCC1CC2 RNTGAALAVHDESG-UNTBIKODSA-N 0.000 description 1
- BCZLMXJDECUUDW-UHFFFAOYSA-N CC(=O)C1=C2CCCCC2=CC=C1 Chemical compound CC(=O)C1=C2CCCCC2=CC=C1 BCZLMXJDECUUDW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000206576 Chondrus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- JQBPISLBTDBKBJ-OGFXRTJISA-N [HH].[H][C@@]1(N)CN2CCC1CC2 Chemical compound [HH].[H][C@@]1(N)CN2CCC1CC2 JQBPISLBTDBKBJ-OGFXRTJISA-N 0.000 description 1
- UKUDKGCYXPIZRH-QGZVFWFLSA-N [H][C@@]1(NC(=O)C2=C3CCCCC3=CC=C2)CN2CCC1CC2 Chemical compound [H][C@@]1(NC(=O)C2=C3CCCCC3=CC=C2)CN2CCC1CC2 UKUDKGCYXPIZRH-QGZVFWFLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940014175 aloxi Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- LJYKLCIKULCTDF-UHFFFAOYSA-N benzo[de]isoquinolin-1-one Chemical compound C1=CC(C(=O)N=C2)=C3C2=CC=CC3=C1 LJYKLCIKULCTDF-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Definitions
- the present invention is directed to new crystalline forms of Palonosetron hydrochloride, and processes for preparation thereof and pharmaceutical compositions thereof.
- Palonosetron hydrochloride and its preparation were first reported in U.S. Pat. No. 5,202,333. Also, reported is the isolation of Palonosetron hydrochloride by crystallization from ethanol, providing Palonosetron hydrochloride with a melting point of 296-297° C.
- the mixture was distilled to a volume of approximately 16 L, cooled over 2 hours to 20° C. and then cooled to 5° C. and stirred for approximately 18 hours giving a crystalline precipitate.
- the precipitate was isolated by filtration and dried in a nitrogen/vacuum oven at 68° C.”
- polymorphism The occurrence of different solid state forms (polymorphism) is a property of some molecules and molecular complexes.
- a single molecule like the Palonosetron hydrochloride in the above formula may give rise to a variety of solids having distinct physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint and NMR spectrum.
- the differences in the physical properties of polymorphs result from the orientation and intermolecular interactions of adjacent molecules (complexes) in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous and/or disadvantageous physical properties compared to other forms in the polymorph family.
- One of the most important physical properties of pharmaceutical polymorphs is their solubility in aqueous solution.
- the present invention provides crystalline form of Palonosetron hydrochloride characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD substantially as depicted in FIG. 1 , and a combination thereof.
- the present invention provides a process for preparing crystalline Palonosetron hydrochloride characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD substantially as depicted in FIG. 1 , and a combination thereof, comprising crystallizing Palonosetron hydrochloride having less than 65% of Palonosteron 3aS Palonostreon HCl of the following formula,
- a solvent selected from the group consisting of methanol, a mixture of isoproanol and water, and a mixture of methanol, isoproanol and water at a temperature below 55° C.
- the present invention provides crystalline form of Palonosetron hydrochloride characterized by data selected form the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD substantially as depicted in FIG. 2 , and a combination thereof.
- the present invention provides a process for preparing crystalline Palonosetron hydrochloride characterized by data selected form the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD substantially as depicted in FIG. 2 , and a combination thereof, comprising crystallizing Palonosetron hydrochloride having at least 96% of Palonosteron 3aS Palonostreon HCl of the following formula,
- the present invention provides another process for preparing crystalline Palonosetron hydrochloride characterized data selected form the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD substantially as depicted in FIG. 2 , and a combination thereof, comprising exposing crystalline Palonosetron hydrochloride characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD substantially as depicted in FIG. 1 , and a combination thereof to relative humidity of 100%.
- the present invention provides a pharmaceutical composition comprising at least one of the crystalline forms of Palonosetron hydrochloride of the present invention and a pharmaceutically acceptable excipient.
- the present invention provides a process for preparing a pharmaceutical composition comprising at least one of the crystalline forms of Palonosetron hydrochloride of the present invention and a pharmaceutically acceptable excipient.
- the present invention provides pharmaceutical formulations comprising at least one of the crystalline forms of Palonosetron hydrochloride prepared according to the processes of the present invention, and a pharmaceutically acceptable excipient.
- the present invention provides a process for preparing pharmaceutical formulations comprising at least one of the crystalline forms of Palonosetron hydrochloride prepared according to the processes of the present invention, and a pharmaceutically acceptable excipient.
- FIG. 1 illustrates X-ray powder diffraction pattern of crystalline Palonosetron HCl characterized by data selected from the group consisting of: PXRD with peaks at about 13.0, 15.4 and 17.5 degrees two-theta, a PXRD substantially as depicted in FIG. 1 , and a combination thereof.
- FIG. 2 illustrates X-ray powder diffraction pattern of crystalline Palonosetron HCl characterized by data selected from the group consisting of: a PXRD with peaks at about 12.1, 15.8 and 17.3 degrees two-theta, a PXRD figure as depicted in FIG. 2 , and a combination thereof.
- the present invention provides novel crystalline forms of Palonosetron hydrochloride (referred to as PAL-HCl), processes for making them, and pharmaceutical compositions thereof.
- PAL-HCl novel crystalline forms of Palonosetron hydrochloride
- the present invention provides crystalline form of PAL-HCl characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 1 , and a combination thereof.
- the said crystalline form can be further characterized by a PXRD with peaks at about 7.1, 13.7, 14.2, 16.2, 18.5, 20.0 and 22.1 ⁇ 0.2 degrees two-theta.
- the said crystalline form of PAL-HCl can also be characterized by a DSC thermogram having an endothermic peak at about 311° C. due to melting.
- the above crystalline form can be characterized by a weight loss of less than about 0.1% measured at temperatures less or equal to 153° C. by TGA.
- the above crystalline form is an anhydrous form of PAL-HCl.
- the said crystalline form of PAL-HCl has less than 20%, preferably less than 10%, more preferably less than 5% of the crystalline Palonosetron hydrochlroide characterized by data selected from the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 2 , and a combination thereof.
- the content of crystalline Palonosetron hydrochlroide characterized by data selected from the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 2 , and a combination thereof is measured by % by weight, preferably as determined by PXRD.
- the above crystalline PAL-HCl is prepared by a process comprising crystallizing Palonosetron hydrochloride having less than 65% of 3aS Palonosetron HCl of the following formula,
- a solvent selected from the group consisting of: methanol, a mixture of isopropanol and water, and a mixture of methanol, isopropanol and water, at a temperature below 55° C.
- the crystallization process comprises providing a solution of PAL-HCl having less than 65% of 3aS Palonosetron HCl in a solvent selected from the group consisting: methanol, a mixture of isopropanol and water, and a mixture of methanol, isopropanol and water, and precipitating the said crystalline PAL-HCl at a temperature below 55° C.
- the content of the 3aS Palonostreon HCl isomer in Palonostreon HCl is of about 65% to about 50%.
- the measurement of the content of the 3aS Palonostreon HCl isomer in Palonostreon HCl is by % area, preferably, by HPLC.
- the above solution is preferably, prepared by a process comprising combining PAL-HCl having less than 65% of 3aS Palonostreon HCl and a solvent at a temperature of about 25° C. to about reflux to obtain said solution.
- the solution of PAL-HCl in methanol is provided by combining PAL-HCl and methanol at a temperature of about 10° C. to about 30° C., preferably of about 20° C. to about 25° C., more preferably of about 25° C.
- the solution of PAL-HCl in a mixture of IPA and water is provided by combining PAL-HCl having less than 65% of 3aS Palonosetron HCl and a mixture of EPA and water at a temperature of at least about 75° C.
- the solution of PAL-HCl in a mixture of methanol, IPA and water is provided by combining a methanolic residue of PAL-HCl having less than 65% of 3aS Palonosetron HCl with a mixture of EPA and water at a temperature of at least 75° C.
- the methanolic residue of PAL-HCl having less than 65% of 3aS Palonosetron HCl can be prepared by a process comprising concentrating a solution of PAL-HCl having less than 65% of 3aS Palonosetron HCl in methanol to obtain a concentrated solution, adding IPA or a mixture of IPA and water to obtain a mixture, concentrating the mixture to obtain said methanolic residue. This process may be repeated.
- the ratio of the solvents in the mixture of IPA-water is of about 94:6 to about 97:3, more preferably, of about 95:5 to about 97:3, respectively.
- combining PAL-HCl having less than 65% of 3aS Palonosetron HCl or a methanolic residue thereof with a mixture of EPA and water is done at about 75° C. to about 90° C., more preferably at about 77° C. to about 85° C., even more preferably, at about 77° C. to about 80° C., most preferably, at reflux temperature.
- the reflux temperature may vary according to the total amount of water.
- water can be present in the solution in a total amount of about 2 to about 6% V/V.
- the solution obtained in this process of the present invention may comprise methanol, IPA and water in a ratio of about 0.5:94.5:5 to about 0.1:94.9:5 V/V, respectively.
- Precipitation can be achieved by cooling the solution, by evaporating the solvent or by combination of both, wherein both are done at a temperature below 55° C.
- the precipitation is achieved, preferably, by evaporating the solution at a temperature of about 10° C. to about 30° C., more preferably at about 20° C. to about 25° C., even more preferably of about 25° C.
- the precipitation is achieved, preferably, by cooling the solution at a temperature below about 55° C. in order to obtain a suspension, preferably, to a temperature of about 48-52° C., then the temperature is further decreased to about 0° C., more preferably, to a temperature 25° C. to about 0° C., to obtain a suspension, increasing the recovery yield.
- the amount of precipitated crystalline product may be increased by a process comprising at least one of the following steps: concentrating the second suspension, and further maintaining the second suspension at such cooled temperature for a sufficient period of time.
- concentration is carried out at a temperature of about 45° C. to about 55° C.
- the suspension is further maintained at a temperature of about 25° C. to about 0° C., more preferably, of about 10° C. to about 0° C.
- the second suspension is maintained for about 10 to about 24 hours, more preferably, for about 15 to about 20 hours.
- the process for preparing the above characterized crystalline PAL-HCl may further comprise a recovery process.
- This crystalline PAL-HCl may be recovered by any process known to a skilled artisan, such as filtering and/or drying.
- the present invention also provides crystalline PAL-HCl characterized by data selected from the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 2 , and a combination thereof.
- This crystalline can be further characterized by said PXRD pattern with peaks at about 7.1, 13.8, 14.2, 14.5, 18.5, 20.0 and 30.3 ⁇ 0.2 degrees two-theta.
- Said crystalline PAL-HCl can be further characterized by a DSC thermogram having an endothermic peak at about 313° C. due to melting.
- the above crystalline PAL-HCl can be characterized by a weight loss of less than about 0.1% measured at temperatures less or equal to 152° C. by TGA.
- the above crystalline PAL-HCl is an anhydrous form of PAL-HCl.
- This crystalline PAL-HCl has less than 20%, preferably, less than 10%, more preferably, less than 5% of crystalline Palonosetron hydrochlroide characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 1 , and a combination thereof.
- the content of crystalline Palonosetron hydrochlroide characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 1 , and a combination thereof may be measured by % by weight, preferably, by PXRD.
- the crystalline PAL-HCl data selected from the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 2 , and a combination thereof is prepared by a process comprising crystallizing Palonosetron hydrochloride having at least 96% of 3aS Palonosetron HCl of the following formula,
- crystallization is carried out by providing a solution of PAL-HCl having at least 96% of 3aS Palonostreon HCl, in a mixture comprising IPA and water at a temperature above 55° C., and precipitating the said crystalline PAL-HCl at a temperature of at least about 55° C.
- the measurement of the content of the 3aS Palonostreon HCl isomer in Palonostreon HCl is by % area, preferably, by HPLC.
- the solution is provided by a process comprising admixing PAL-HCl having at least 96% of 3aS Palonostreon HCl with a mixture comprising EPA and water to obtain a suspension, and heating the suspension to a temperature above 55° C.
- the starting PAL-HCl may be a dry solid.
- dry in reference to PAL-HCl, as used herein, refers to a solid that doesn't lose any weight when being dried.
- the ratio of the solvents in the mixture of IPA-water is of about 94:6 to about 98:2, more preferably, of about 95:5 to about 98:2, respectively.
- the suspension is heated to a temperature of at least 75° C., preferably, at about 75° C. to about 90° C., more preferably about 77° C. to about 85° C., even more preferably, at about 77° C. to about 80° C., most preferably, at reflux temperature.
- the reflux temperature may vary according to the total amount of water.
- water can be present in the solution in a total amount of about 2 to about 6% V/V.
- precipitation is achieved by cooling the solution to a temperature of at least about 55° C., preferably about 58° C. to about 60° C., to obtain a suspension.
- the amount of precipitated crystalline product may be increased by a process comprising at least one of the following steps: cooling the obtained suspension, concentrating the obtained suspension, and further maintaining the second suspension at such temperature for a sufficient period of time, or any combination thereof.
- concentration is carried out at a temperature of about 50° C. to about 40° C.
- the suspension is further maintained at a temperature of about 20° C. to about 0° C.
- the second suspension is maintained for about 10 to about 18 hours, more preferably, for about 30 min to about 18 hours.
- the process for preparing the above crystalline PLA-HCl may further comprise a recovery process.
- the said crystalline form may be recovered by any process known to a skilled artisan, such as filtering and drying.
- Crystalline Palonosetron hydrochloride characterized by data selected form the group consisting of: a PXRD having peak reflections at about 12.1, 15.8 and 17.3 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 2 , and a combination thereof can be prepared by another process comprising exposing crystalline Palonosetron hydrochloride characterized by data selected from the group consisting of: a PXRD having peak reflections at about 13.0, 15.4 and 17.5 ⁇ 0.2 degrees two-theta, a PXRD pattern substantially as depicted in FIG. 1 , and a combination thereof to relative humidity of 100%.
- the starting crystalline PAL-HCl is exposed to relative humidity of 100% at a temperature of about 20° C. to about 30° C. (room temperature), for a period of about 2 days to about 10 days, preferably about 4 to about 8 days, and more preferably about 7 days.
- the starting PAL-HCl for preparing any of the crystalline forms of PAL-HCL of the present invention can be obtained, for example, according to the processes described in co-pending application Ser. No. 11/_______ (Attorney Docket 13150/48504), filed Oct. 23, 2007.
- the process comprises reacting Cp 9588 of the following formula,
- the crystalline forms of the present invention can be used in a pharmaceutical composition for treatment for prevention of chemotherapy-induced nausea and vomiting.
- the present invention provides a pharmaceutical composition comprising at least one of the crystalline forms of Palonosetron hydrochloride of the present invention and a pharmaceutically acceptable excipient.
- the present invention also provides a process for preparing a pharmaceutical composition comprising at least one of the crystalline forms of Palonosetron hydrochloride of the present invention and a pharmaceutically acceptable excipient.
- compositions of the present invention can be administered in various preparations depending on the age, sex, and symptoms of the patient.
- the pharmaceutical compositions can be administered, for example, as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injection preparations (solutions and suspensions), and the like.
- compositions of the present invention can optionally be mixed with other forms of Palonosetron hydrochloride and/or other active ingredients.
- pharmaceutical compositions of the present invention can contain inactive ingredients such as diluents, carriers, fillers, bulking agents, binders, disintegrants, disintegration inhibitors, absorption accelerators, wetting agents, lubricants, glidants, surface active agents, flavoring agents, and the like.
- Diluents increase the bulk of a solid pharmaceutical composition and can make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle.
- Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), microfine cellulose, lactose, starch, pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, or talc.
- microcrystalline cellulose e.g., Avicel®
- microfine cellulose lactose
- starch pregelitinized starch
- calcium carbonate calcium sulfate
- sugar dextrates
- Carriers for use in the pharmaceutical compositions may include, but are not limited to, lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, or silicic acid.
- Binderk help bind the active ingredient and other excipients together after compression.
- Binders for solid pharmaceutical compositions include for example acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®, liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, or starch.
- carbomer e.g. carbopol
- carboxymethylcellulose sodium dextrin
- ethyl cellulose gelatin
- guar gum hydrogenated vegetable oil
- hydroxyethyl cellulose hydroxypropyl cellulose
- Disintegrants can increase dissolution.
- Disintegrants include, for example, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch.
- alginic acid carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powder
- Disintegration inhibitors may include, but are not limited to, white sugar, stearin, coconut butter, hydrogenated oils, and the like.
- Absorption accelerators may include, but are not limited to, quaternary ammonium base, sodium laurylsulfate, and the like.
- Wetting agents may include, but are not limited to, glycerin, starch, and the like.
- Adsorbing agents used include, but are not limited to, starch, lactose, kaolin, bentonite, colloidal silicic acid, and the like.
- Lubricants include for example magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
- Glidants can be added to improve the flowability of non-compacted solid composition and improve the accuracy of dosing.
- Excipients that can function as glidants include for example colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.
- Flavoring agents and flavor enhancers make the dosage form more palatable to the patient.
- Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present invention include for example maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
- Tablets can be further coated with commonly known coating materials such as sugar coated tablets, gelatin film coated tablets, tablets coated with enteric coatings, tablets coated with films, double layered tablets, and multi-layered tablets.
- Capsules can be coated with shell made, for example, from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
- Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
- the Palonosetron hydrochloride of the present invention is suspended, while maintaining its crystalline characteristics, and any other solid ingredients are dissolved or suspended in a liquid carrier, such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
- a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
- Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier.
- Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.
- Liquid pharmaceutical compositions of the present invention can also contain viscosity enhancing agents to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract.
- agents include for example acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.
- Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar can be added to improve the taste.
- Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid can be added at safe levels to improve storage stability.
- a liquid composition according to the present invention can also contain a buffer such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate.
- a buffer such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate.
- a composition for tableting or capsule filing can be prepared by wet granulation.
- wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, which causes the powders to clump up into granules.
- the granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size.
- the granulate can then be tableted or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.
- a tableting composition can be prepared conventionally by dry blending.
- the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules.
- the compacted granules can be compressed subsequently into a tablet.
- a blended composition can be compressed directly into a compacted dosage form using direct compression techniques.
- Direct compression produces a more uniform tablet without granules.
- Excipients that are particularly well-suited to direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
- a capsule filling of the present invention can comprise any of the aforementioned blends and granulates that were described with reference to tableting, only they are not subjected to a final tableting step.
- any commonly known excipient used in the art can be used.
- carriers include, but are not limited to, lactose, starch, coconut butter, hardened vegetable oils, kaolin, talc, and the like.
- Binders' used include, but are not limited to, gum arabic powder, tragacanth gum powder, gelatin, ethanol, and the like.
- Disintegrating agents used include, but are not limited to, agar, laminalia, and the like.
- excipients include, but are not limited to, polyethylene glycols, coconut butter, higher alcohols, esters of higher alcohols, gelatin, semisynthesized glycerides, and the like.
- injectable pharmaceutical compositions When preparing injectable pharmaceutical compositions, solutions and suspensions are sterilized and are preferably made isotonic to blood.
- injection preparations may use carriers commonly known in the art.
- carriers for injectable preparations include, but are not limited to, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and fatty acid esters of polyoxyethylene sorbitan.
- carriers for injectable preparations include, but are not limited to, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and fatty acid esters of polyoxyethylene sorbitan.
- dissolving agents such as dissolving agents, buffer agents, and analgesic agents may be added.
- coloring agents, preservatives, perfumes, seasoning agents, sweetening agents, and other medicines may also be added to the desired preparations during the treatment of schizophrenia.
- the amount of Palonosetron hydrochloride of the present invention contained in a pharmaceutical composition according to the present invention is not specifically restricted; however, the dose should be sufficient to treat, ameliorate, or reduce the condition.
- ARL X-ray powder diffractometer model X′TRA-030, Peltier detector, round standard aluminum sample holder with round zero background quartz plate was used.
- the accuracy of peak positions is defined as +/ ⁇ 0.2 degrees due to experimental differences like instrumentations, and sample preparations.
- a solution of about 3.5 g of palonosetron hydrochloride diastereoisomeric mixture (60.5% 3aS isomer, 39.6% 3aR isomer) in 90 ml of MeOH was concentrated to 12 mL of residual volume under vacuum. 38 mL of a mixture isopropanol-water 97:3 were added at reflux temperature leading to a solution. The solvent was evaporated at atmospheric pressure to 28 mL residual volume in order to eliminate most of the residual MeOH. To the suspension further 28 mL of mixture isopropanol-water 97:3 were added at reflux temperature to achieve complete dissolution. The solution was cooled in 100 minutes to 50° C., leading to the seeding of the solid. The mixture was concentrated under vacuum at 50° C.
- step 1 To the suspension, at 60 ⁇ 2° C., the toluenic solution of acyl chloride obtained in step 1 was added dropwise in about 1 hour. After 30 minutes the reaction was considered complete, thus 200 mL of water were added.
- the organic phase was concentrated under reduced pressure, with internal temperature 55 ⁇ 2° C. until 180 mL of residual volume.
- the layers were separated and 50 mL of a solution of NaCl 15% w/w in water (prepared dissolving 7.5 g of NaCl pellets in about 42.5 mL of water) were added to the organic phase.
- the suspension was heated to 50 ⁇ 2° C. and 100 mL of n-heptane were charged at this temperature.
- the suspension was cooled to 70 ⁇ 2° C. in 120 minutes, then after 30 minutes of stirring at this temperature the solid was filtered off washing the cake with a mixture of 15 mL of IPA and 15 mL of n-heptane pre-cooled to 0 ⁇ 2° C.
- the suspension was heated to 50° C. and stirred in these conditions for 21 hours (adding H 2 when internal pressure ⁇ 3 bar). The suspension was then cooled to 5 ⁇ 2° C. and 2.56 g of solution of SO 2 5% in water were added to quench the reaction.
- the wet solid was dried at 70° C. for a 18 hours under vacuum, leading to 2.9 g of Palonosetron HCl.
- the polymorphic form of the material was measured by X-ray powder diffraction after 1 week storage.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Otolaryngology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/311,819 US20100016593A1 (en) | 2006-10-23 | 2007-10-23 | Crystalline forms of palonosetron hydrochloride |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85384006P | 2006-10-23 | 2006-10-23 | |
US86148806P | 2006-11-28 | 2006-11-28 | |
US86184706P | 2006-11-29 | 2006-11-29 | |
US89910207P | 2007-02-01 | 2007-02-01 | |
US89910907P | 2007-02-01 | 2007-02-01 | |
US91916507P | 2007-03-20 | 2007-03-20 | |
US95567907P | 2007-08-14 | 2007-08-14 | |
US12/311,819 US20100016593A1 (en) | 2006-10-23 | 2007-10-23 | Crystalline forms of palonosetron hydrochloride |
PCT/US2007/022539 WO2008051564A2 (fr) | 2006-10-23 | 2007-10-23 | Formes cristallines d'hydrochlorure de palonosetron |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100016593A1 true US20100016593A1 (en) | 2010-01-21 |
Family
ID=39271334
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/977,419 Expired - Fee Related US7737280B2 (en) | 2006-10-23 | 2007-10-23 | Processes for preparing palonosetron salts |
US12/311,819 Abandoned US20100016593A1 (en) | 2006-10-23 | 2007-10-23 | Crystalline forms of palonosetron hydrochloride |
US13/336,270 Abandoned US20120122915A1 (en) | 2006-10-23 | 2011-12-23 | Crystalline forms of palonosetron hydrochloride |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/977,419 Expired - Fee Related US7737280B2 (en) | 2006-10-23 | 2007-10-23 | Processes for preparing palonosetron salts |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/336,270 Abandoned US20120122915A1 (en) | 2006-10-23 | 2011-12-23 | Crystalline forms of palonosetron hydrochloride |
Country Status (5)
Country | Link |
---|---|
US (3) | US7737280B2 (fr) |
EP (3) | EP2103612A1 (fr) |
HR (1) | HRPK20100281B3 (fr) |
IL (3) | IL198284A0 (fr) |
WO (2) | WO2008051539A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614225B2 (en) | 2006-08-30 | 2013-12-24 | Dr. Reddy's Laboratories Limited | Process for the purification of palonosetron or its salt |
WO2008073757A1 (fr) | 2006-12-07 | 2008-06-19 | Helsinn Healthcare Sa | Formes cristallines et amorphes d'hydrochlorure de palonosétron |
WO2009010987A1 (fr) * | 2007-07-19 | 2009-01-22 | Natco Pharma Limited | Procédé amélioré pour la préparation de chlorhydrate de palonosétron pur |
WO2009087643A1 (fr) * | 2008-01-11 | 2009-07-16 | Natco Pharma Limited | Nouvelles formes cristallines du chlorhydrate de palonosétron |
WO2009136405A1 (fr) * | 2008-05-05 | 2009-11-12 | Natco Pharma Limited | Palonosétron de pureté élevée et ses caractéristiques à l’état solide |
EP2364312A4 (fr) | 2008-11-11 | 2012-05-02 | Reddys Lab Ltd Dr | Synthèse de chlorhydrate de palonosétron cristallin |
US20100143461A1 (en) * | 2008-12-08 | 2010-06-10 | Ben-Zion Solomon | Palonosetron formulation |
US20120267533A1 (en) | 2009-06-30 | 2012-10-25 | Ranbaxy Laboratories Limited | Processes for the preparation of form i and form ii of palonosetron hydrochloride |
CN107328880B (zh) * | 2017-08-09 | 2019-11-22 | 杭州新博思生物医药有限公司 | 一种反相色谱分离盐酸帕洛诺司琼注射液有关物质的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202333A (en) * | 1989-11-28 | 1993-04-13 | Syntex (U.S.A.) Inc. | Tricyclic 5-HT3 receptor antagonists |
US5510486A (en) * | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
US20080058367A1 (en) * | 2006-08-30 | 2008-03-06 | Palle Raghavendracharyulu Venk | Process for the purification of palonosetron or its salt |
US20110021778A1 (en) * | 2009-07-21 | 2011-01-27 | Sugata Chatterjee | Process for the Preparation of Substantially Pure Palonosetron and its Acid Salts |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567818A (en) | 1994-07-08 | 1996-10-22 | Syntex (U.S.A.) Inc. | Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein |
WO2008073757A1 (fr) | 2006-12-07 | 2008-06-19 | Helsinn Healthcare Sa | Formes cristallines et amorphes d'hydrochlorure de palonosétron |
-
2007
- 2007-10-23 WO PCT/US2007/022479 patent/WO2008051539A2/fr active Application Filing
- 2007-10-23 EP EP09007479A patent/EP2103612A1/fr not_active Withdrawn
- 2007-10-23 US US11/977,419 patent/US7737280B2/en not_active Expired - Fee Related
- 2007-10-23 EP EP07839759A patent/EP1960397A2/fr not_active Withdrawn
- 2007-10-23 US US12/311,819 patent/US20100016593A1/en not_active Abandoned
- 2007-10-23 EP EP07839753A patent/EP1966197A2/fr not_active Withdrawn
- 2007-10-23 WO PCT/US2007/022539 patent/WO2008051564A2/fr active Application Filing
-
2009
- 2009-04-22 IL IL198284A patent/IL198284A0/en unknown
- 2009-04-22 IL IL198283A patent/IL198283A0/en unknown
-
2010
- 2010-05-21 HR HR20100281A patent/HRPK20100281B3/xx not_active IP Right Cessation
- 2010-06-20 IL IL206479A patent/IL206479A0/en unknown
-
2011
- 2011-12-23 US US13/336,270 patent/US20120122915A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202333A (en) * | 1989-11-28 | 1993-04-13 | Syntex (U.S.A.) Inc. | Tricyclic 5-HT3 receptor antagonists |
US5510486A (en) * | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
US20080058367A1 (en) * | 2006-08-30 | 2008-03-06 | Palle Raghavendracharyulu Venk | Process for the purification of palonosetron or its salt |
US20110021778A1 (en) * | 2009-07-21 | 2011-01-27 | Sugata Chatterjee | Process for the Preparation of Substantially Pure Palonosetron and its Acid Salts |
Also Published As
Publication number | Publication date |
---|---|
WO2008051564A3 (fr) | 2008-06-19 |
US20120122915A1 (en) | 2012-05-17 |
IL198283A0 (en) | 2010-02-17 |
HRPK20100281B3 (en) | 2012-01-31 |
HRP20100281A2 (hr) | 2010-10-31 |
US20080200681A1 (en) | 2008-08-21 |
US7737280B2 (en) | 2010-06-15 |
WO2008051539A3 (fr) | 2008-07-31 |
WO2008051539A2 (fr) | 2008-05-02 |
IL206479A0 (en) | 2010-12-30 |
WO2008051564A2 (fr) | 2008-05-02 |
EP1966197A2 (fr) | 2008-09-10 |
EP1960397A2 (fr) | 2008-08-27 |
IL198284A0 (en) | 2010-02-17 |
EP2103612A1 (fr) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120122915A1 (en) | Crystalline forms of palonosetron hydrochloride | |
US20230183235A1 (en) | Solid state forms of amg-510 and process for preparation thereof | |
US20060160785A1 (en) | Ezetimibe polymorphs | |
US20080090835A1 (en) | Polymorphic forms of ziprasidone HCl and processes for their preparation | |
MX2007016179A (es) | Formas cristalinas de o-desmetilvenlafaxina. | |
US20080114028A1 (en) | Process for preparing polymorphic forms of solifenacin succinate | |
US20070203177A1 (en) | Forms of dolasetron mesylate and processes for their preparation | |
US7417165B2 (en) | Crystalline forms of pregabalin | |
EP2093224A1 (fr) | Prodédé de préparation de la forme bêta de l'hydrobromide d'élétriptan crystallin | |
US20070093458A1 (en) | Preparation of paricalcitol and crystalline forms thereof | |
WO2022060758A1 (fr) | Formes à l'état solide de sep-363856 et leur procédé de préparation | |
US20040235904A1 (en) | Crystalline and amorphous solids of pantoprazole and processes for their preparation | |
US20220356165A1 (en) | Solid state forms of roluperidone and salts thereof | |
WO2007016208A2 (fr) | Sel d'ammonium d'acide 1,2-benzisoxazole-3-methane-sulfonique | |
US20220289764A1 (en) | Crystalline lorlatinib : fumaric acid and solid state form thereof | |
WO2023199258A1 (fr) | Formes à l'état solide de mavacamten et leur procédé de préparation | |
WO2024062344A1 (fr) | Formes à l'état solide de mesdopétam et leurs sels | |
US20080027128A1 (en) | Duloxetine HCL polymorphs | |
US20080161412A1 (en) | Process for preparation of sertraline hydrochloride form I | |
EP4271678A1 (fr) | Formes solides de capivasertib et leur procédé de préparation | |
WO2007016209A2 (fr) | Sel de sodium d'acide 1,2-benzisoxazole-3-methane-sulfonique pur et procede de purification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SICOR INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSSETTO, PIERLUIGI;MACDONALD, PETER LINDSAY;BANFI, GAIA;AND OTHERS;SIGNING DATES FROM 20120712 TO 20120718;REEL/FRAME:028630/0064 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |